Empowering Market Access Evolution in Japan
Empowering Market Access Evolution in Japan
To Make The Difference Let’s Be Clever Together
Clever-Access Japan is a Japanese consulting partner that supports market access and social implementation of innovative medical technologies, including pharmaceuticals and medical devices. Leveraging Clever-Access's global track record, scientific evidence, and advanced data analysis technology, we provide comprehensive support from market entry (market access) to insurance coverage and value creation, contributing to a better future for Japan's medical and life sciences fields.
In the increasingly complex healthcare market, we provide highly customized strategic solutions and specialized services to help companies, venture startups, researchers, policymakers, and patient groups make evidence-based decisions.
The Importance of Market Access Strategy in the Japanese Market
For medical technologies to enter the market, it is essential to demonstrate not only the efficacy and safety of the product but also its alignment with patient and clinical needs, economic viability within the regulatory framework, and compliance with policy priorities. Clever-Access Japan provides customized access strategies tailored to the Japanese market, taking into account the actual state of regulatory frameworks and policy evaluation perspectives.
Main Services in Japan
To deliver innovative medical technologies to patients, we design integrated strategies combining market access, reimbursement and HEOR (Health Economics and Outcomes Research).
Feasibility assessment for Japan and overseas markets
Strategic planning and application support for reimbursement
Market Access- and HEOR-integrated strategic design
Decision-making support based on policy trends
As the information and decision-making criteria sought by various stakeholders become increasingly diverse and specialized, the ability to clearly communicate the value of medical technologies is becoming increasingly important. We support the design and implementation of strategic communication that connects science with society to ensure that product value is effectively communicated to stakeholders.
For physicians and healthcare professionals, we provide real-world evidence (RWE) and economic impact data to support decision-making in clinical settings, as well as evidence-based materials such as academic papers, conference presentations, and educational resources.
For policymakers, we clarify the benefits within the overall system, demonstrate cost-saving effects, and address access challenges through value proposition materials.
For patient organizations, we design strategic communication to demonstrate a visualization of how medical technologies contribute to quality of life, and highlight the importance of medical needs and access.
In Japan, HTA currently serves as reference information for drug price adjustments, which is different from European countries. However, in recent years, the institutional use of cost-effectiveness evaluation has progressed, making it an important factor for companies in maintaining drug prices and justifying their value.
We view HTA as a strategic opportunity to communicate value and provide support tailored to Japan's unique institutional environment. We offer comprehensive support, from strategic design for cost-effectiveness analysis (CEA) to assistance with public reviews.
Clinical trial design taking into consideration cost-effectiveness analysis
Cost-Effectiveness Analysis (CEA) and Economic Modeling
Preparation of Health Technology Assessment (HTA) reports
Support for responding to public agency reviews
We provide support through workshops and other means to optimize the structure of the organization responsible for the company's market access strategies and to strengthen specific measures related to strategies for creating product value.
Organizational design and streamlining of cross-functional roles (R&R, roadmap development, etc.)
Support for collaboration with global counterparts and localization (designing implementation plans aligned with global strategies while adapting to Japanese systems and customs, conducting workshops, etc.)
Analysis and Evidence Building Support
We provide reliable, evidence-based information to address complex healthcare challenges by leveraging the following specialized technologies:
High-precision analytical solutions including large-scale data analysis and real-world evidence (RWE) analysis
Structural integration of multiple evidence sources through systematic reviews, meta-analyses, and network meta-analyses
Cost-effectiveness analysis (CEA), burden of illness assessment (BOI), value information assessment, and other models to support strategic decision-making
What We Aim to Achieve
"To make the difference, let’s be clever together"
Clever-Access Japan serves as a trusted partner throughout all stages from medical research and development to implementation in society. Our mission is to identify needs based on social issues, create value through evidence and strategy, and help deliver healthcare that reaches patients in collaboration with all stakeholders.
A Collaborative Partner in Shaping the Future
Clever-Access Japan is not merely an advisor, but a "partner" who deeply engages with medical practice, policy, and social issues and moves forward together. Under the philosophy of "to make the difference, let’s be clever together" we will continue to provide our full support for the sustainable development of healthcare in Japan and for innovative medical technologies that improve the lives of every individual.
contact@clever-access.com
Consultation and Inquiries
We offer consultations tailored to your company's stage, from initial feasibility assessments to insurance coverage and value communication strategies. Please feel free to contact us. We can accommodate both Japanese and English.